The Influence of (R)- and (S)-Warfarin, Vitamin K and Vitamin K Epoxide upon Warfarin Anticoagulation

Summary

The contribution of (R)and (S)-warfarin enantiomers, vitamin K and vitamin K epoxide and patient factors to inter-individual variability in daily warfarin requirements were examined in a group of 73 patients. Simple correlation analysis showed a significant positive relationship between INR values and plasma (S)-warfarin concentrations (r = 0.25; p = 0.038). Multivariate analysis for relationships with INR demonstrated a highly significant positive relationship between INR and (S)- warfarin (p = 0.004) and plasma vitamin K epoxide concentrations (p = 0.028), and a significant negative relationship between INR and plasma vitamin K concentrations (p = 0.034). Twenty five percent of variation in INR could be explained by these variables (adjusted R² = 0.25). Correlation analysis of data showed that warfarin dosage was significantly and negatively correlated with patient age (r = −0.42; p <0.0001). Patient age accounted for 25% of variation in warfarin dosage requirements (R² = 0.25). The combined effects of age and vitamin K appear to account for much of the inter-individual variability in warfarin dosage requirements.

Keywords

Warfarin - anticoagulation - vitamin K - vitamin K epoxide - ageing

• References

• 1 Peterson C, Kwaan HC. Current concepts of warfarin therapy. Arch Intern Med 1986; 146: 581-4.
• 2 Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled date from five randomised controlled trials. Arch Intern Med 1994; 154: 1449-57.
• 3 Sudlow M, Thomson R, Thwaites B, Rogers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulant in the community. Lancet 1998; 352: 1167-71.
• 4 Routledge PA, Chapman PH, Davies DM, Rawlins MD. Factors affecting warfarin requirements – a prospective population study. Eur J Clin Pharm 1979; 15: 319-22.
• 5 Furuya H, Fernandez-Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effects on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995; 05: 389-92.
• 6 Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at that start of outpatient therapy. Am J Med 1989; 87: 144-52.
• 7 O’Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmac Ther 1974; 16: 348-54.
• 8 Lewis RJ, Trager WF, Chan KK, Breckenridge AM, Orme M, Rowland M, Schary W. Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 1974; 53: 1607-17.
• 9 Naidong W, Lee JW. Development and validation of a high performance liquid chromatographic method for the quantification of warfarin enantiomers in human plasma. J Pharm Biomed Anal 1993; 11: 785-92.
• 10 Davidson KW, Sadowski JA. Determination of vitamin K compounds in plasma or serum by high performance liquid chromatography using postcolumn chemical reduction and fluorimetric detection. Methods Enzymol 1997; 282: 408-21.
• 11 Poller L. Laboratory control of anticoagulants. BMJ 1987; 294: 118.
• 12 Usui Y, Tanimura H, Nishimura N, Kobayashi N, Okanone T, Ozawa K. Vitamin K concentration in the plasma and liver of surgical patients. Am J Clin Nut 1990; 51: 846-52.
• 13 Colvin BT, Lloyd MJ. Severe coagulation defect due to a dietary deficiency of vitamin K. J Clin Pathol 1977; 30: 1147-8.
• 14 Karla PA, Cookin M, Wood G, O’Shea GM, Homes AM. Dietary modification as a cause of anticoagulation instability. Lancet 1988; ii: 803.
• 15 O’Reilly R, Rytand D. Resistance to warfarin due to unrecognised vitamin K supplementation. N Engl J Med 1980; 303: 160.
• 16 Karlson B, Leijd B, Hellstrom K. On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment. Acta Med Scand 1986; 229: 517-20.
• 17 Park BK, Choonara IA, Haynes BP, Breckenridge AM, Malia RG, Present FE. Abnormal vitamin K metabolism in the presence of normal clotting factor activity in factory workers exposed to 4-hydroxycoumarins. Br J Clin Pharmacol 1986; 21: 289-94.
• 18 Choonara IA, Malia RG, Haynes BP, Hay CR, Cholerton S, Breckenridge AM, Preston FE, Park BK. The relationship between inhibition of vitamin K1, 2,3-epoxide reductase and reduction of clotting factor activity with warfarin. Br J Clin Pharmacol 1988; 25: 1-7.
• 19 Shearer MJ, McBurney A, Breckenridge AM, Barkhan P. Effect of warfarin on the metabolism of phylloquinone (vitamin K1): dose-response relationships in man. Clin Sci Mol Med 1977; 52: 621-30.
• 20 Shepherd AM, Christopher LJ, Stevenson CR, Henney CR, Brown Y. A prospective study of the factors affecting anticoagulant control in a hospital outpatient clinic. Postgrad Med J 1978; 54: 784-8.
• 21 O’Malley K, Stevenson IH, Ward CA, Wood AJJ, Crooks J. Determinants of anticoagulant control in patients receiving warfarin. Br J Clin Pharmacol 1977; 04: 309-14.
• 22 Shepherd AM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977; 04: 315-20.
• 23 Hallak HP, Wedlund PJ. Vitamin K epoxide reductase activity and its inhibition by warfarin in young and old rats. Drug Metab Dispos 1991; 19: 278-9.
• 24 Wynne HA, Cope LH, Kelly P, Whittingham T, Edwards C, Kamali F. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol 1995; 40: 203-7.